Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Lee, Ann Sing
Zee, Benny C. Y.
Cheung, Foon Yiu
Kwong, Philip
Cheng, Ashley Chi Kin
Lai, Maria
Kwok, Chloe
Chong, Marc
Jolivet, Jacques
Chiang, C. L.
Leung, K. C.
Siu, Steven
Lee, Conrad
Tung, Stewart Yuk
机构：
[1] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[3] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China
[4] Queen Mary Hosp, North Point, Hong Kong, Peoples R China
[5] Princess Margaret Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Aegera Therapeut Pharmasci Inc, Montreal, PQ, Canada
[7] Princess Margaret Hosp, Kowloon, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4105
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC)
    He, Aiwu Ruth
    Tesfaye, Anteneh
    Smith, Daniel
    Marshall, John
    Pishvaian, Michael J.
    Smaglo, Brandon George
    Weiner, Louis M.
    Dorsch-Vogel, Karen
    Wang, Hongkun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [43] A phase II feasibility study of sorafenib and gemcitabine combination therapy in advanced hepatocellular carcinoma
    Naqi, N.
    Ahmad, S.
    Murad, S.
    Khattak, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [44] A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Rimassa, Lorenza
    Pressiani, Tiziana
    Boni, Corrado
    Carnaghi, Carlo
    Caremoli, Elena Rota
    Fagiuoli, Stefano
    Foa, Paolo
    Salvagni, Stefania
    Cortesi, Enrico
    Tronconi, Maria Chiara
    Personeni, Nicola
    Bozzarelli, Silvia
    Banzi, Maria Chiara
    Fanello, Silvia
    Lutman, Fabio Romano
    Giordano, Laura
    Santoro, Armando
    ONCOLOGIST, 2013, 18 (04): : 379 - 380
  • [45] A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).
    Goyal, Lipika
    Zheng, Hui
    Abrams, Thomas Adam
    Miksad, Rebecca A.
    Bullock, Andrea J.
    Allen, Jill N.
    Yurgelun, Matthew B.
    Sheehan, Susan
    Lynch, Patricia
    Afflitto, Anthony James
    Dinicola, Caroline
    Maurer, Jordan Robert
    Reyes, Stephanie
    Knowles, Michelle
    Galway, Aralee
    Clark, Jeffrey W.
    Birnbaum, Emilie
    Khachatryan, Anna
    Duda, Gabriel Dan
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC)
    Blaszkowsky, L. S.
    Abrams, T. A.
    Miksad, R. A.
    Zheng, H.
    Meyerhardt, J. A.
    Schrag, D.
    Kwak, E. L.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)
    Decaens, T.
    Barone, C.
    Assenat, E.
    Wermke, M.
    Fasolo, A.
    Merle, P.
    Blanc, J. F.
    Grando, V.
    Bruns, R.
    Straub, J.
    Zhao, C.
    Faivre, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 235 - 235
  • [49] Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Peck-Radosavljevic, Markus
    Ma, Yuk Ting
    Graham, Janet
    Fartoux, Laetitia
    Hubner, Richard
    Loembe, Arsene Bienvenu
    Studeny, Matus
    Hocke, Julia
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study
    Sun, W.
    Haller, D. G.
    Mykulowycz, K.
    Rosen, M.
    Soulen, M.
    Capparo, M.
    Faust, T.
    Giantonia, B.
    Olthoff, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345